Ureteric reflux in adults and children treated exclusively by endoscopic Teflon injection: a 10-year experience

Has the data efflux regarding the promising outcome following injection of deflux changed the management of adult vesicoureteral reflux?

Primary vesicoureteral reflux (VUR), traditionally considered a problem of childhood, can also be detected during adulthood. However, while the concept regarding the therapeutic management of VUR in children has undergone revolutionary changes, moving from surgical to conservative approach, the optimal therapeutic approach in adult reflux is poorly addressed and is still unknown. Herein, we review clinical and therapeutic approaches of VUR in pediatric population as published throughout the years. With the introduction of Deflux injection as a minimally invasive procedure, we identify a beginning of a new trend that further extends the indications for endoscopic injections, including its introduction to adult patients as well.

Endoscopic correction of vesicoureteral reflux

Endoscopic subureteral injection of tissue-augmenting substances--a 15-minute outpatient procedure--has become an established alternative to long-term antibiotic prophylaxis and surgical intervention in the treatment of vesicoureteral reflux in children. This report reviews the results of endoscopic treatment of reflux using various tissue-augmenting substances presently available. In terms of effectiveness and long term successful results, PTFE is the most reliable injectable product for the endoscopic treatment of all grades of VUR.